查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014484

經腸營養市場：按產品類型、劑型、給藥途徑、分銷管道和年齡層分類的全球市場預測 – 2026-2032 年

Enteral Nutrition Market by Product Type, Form, Route Of Administration, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，經腸營養市場價值將達到 71 億美元，到 2026 年將成長至 77.4 億美元，到 2032 年將達到 139.9 億美元，年複合成長率為 10.17%。

主要市場統計數據
基準年 2025 71億美元
預計年份：2026年 77.4億美元
預測年份 2032 139.9億美元
複合年成長率 (%) 10.17%

本文旨在透過策略性介紹，解釋為何經腸營養現在需要整合臨床、營運和商業策略，以促進更好的患者療效和系統韌性。

經腸營養在急性和長期臨床護理中發揮核心作用，它將醫療需求與以患者為中心的營養支持相結合。臨床醫生和採購經理越來越認知到，腸內治療不僅僅是一種消耗品，而是護理路徑中不可或缺的一部分。製劑的選擇、給藥途徑和取得模式對治療結果和醫療資源的利用有顯著的影響。因此，明智的決策需要一個綜合的觀點，將臨床證據、供應的連續性和商業性趨勢納入考量。

臨床創新、數位化照護模式和供應鏈現代化如何同時重塑經腸營養的產品設計、處方行為和分銷策略。

經腸營養領域正經歷一場變革，其驅動力包括臨床創新、數位整合以及不斷變化的醫療環境。製劑科學已超越了傳統的熱量補充，將免疫調節、疾病特異性營養混合物和基於微生物組的營養強化等治療方法納入其中。臨床醫生也正根據患者的個別表現型和合併症來最佳化處方實踐。同時，遠端醫療和遠端患者監護的普及使得更嚴格的後續觀察、用藥依從性追蹤和及時的產品調整成為可能，進而影響著產品的設計和包裝要求。

評估 2025 年關稅措施對經腸營養的原料採購、供應鏈韌性和籌資策略的累積影響。

2025年即將實施的進口醫療和營養品關稅措施，使得經腸營養鏈各環節的成本結構和供應鏈風險備受關注。依賴進口原料、特殊配料和成品組件的生產商面臨著不斷上漲的進口成本，這促使他們重新評估籌資策略，並在某些情況下分階段調整產品配方以減輕關稅的影響。為此，採購部門正在加強對總擁有成本（TCO）的審查，並探索合約保障措施，以更公平地分攤供應鏈中的關稅風險。

詳細的細分分析解釋了產品類型、配方、給藥途徑、分銷管道和年齡層如何影響臨床選擇和商業性優先順序。

市場區隔分析揭示了每種產品類型、劑型、給藥途徑、分銷管道和年齡層所面臨的不同機會和挑戰。就產品類型而言，市場包括混合營養食品、特殊營養食品和標準營養食品。特殊營養食品又可細分為疾病特異性療法、膳食纖維強化配方、免疫調節產品和益生菌混合物。疾病特異性產品可針對糖尿病、肝臟、肺部和腎臟疾病等適應症進行客製化。另一方面，標準營養食品則分為模組化、寡聚物或聚合物。這些區分至關重要，因為臨床實踐中的處方行為越來越強調製劑的特異性及其與支持標靶營養介入的證據的一致性。

概述美洲、歐洲、中東、非洲和亞太地區的競爭格局和法規，這些因素決定了製造業的優先事項和打入市場策略。

區域趨勢顯示，美洲、歐洲、中東和非洲以及亞太地區在醫療保健基礎設施、報銷模式和製造地方面存在顯著差異。美洲的特點是醫院系統整合和居家照護市場成熟，與支付方的談判和價值驗證對於產品滲透至關重要。相較之下，歐洲、中東和非洲地區的法規環境和採購方式各不相同，採用集中競標系統、各國特定的臨床指南以及不斷發展的報銷途徑。亞太地區的成長模式則呈現多樣性，既包括特定經濟區強大的國內製造業能力，也包括都市區快速擴張的家庭營養服務。

主要企業如何透過在治療領域進行專業化、供應鏈優勢、建立循證夥伴關係以及提供綜合服務來脫穎而出並確保在臨床環境中得到應用。

經腸營養領域的主要企業正透過整合配方創新、臨床證據的累積以及對供應鏈的投資來脫穎而出。一些企業優先考慮治療領域專業化，開發特異性疾病的配方，並輔以針對性的臨床試驗以及與醫療系統進行的真實世界數據（REW）合作。另一些企業則專注於卓越運營，例如最佳化生產規模、投資品管體係以及拓展低溫運輸和包裝能力，以確保產品完整性。策略夥伴關係、契約製造協議以及與居家照護機構和數位健康平台的合作，正逐漸成為加速產品推廣和提升服務品質的有效途徑。

為加強經腸營養領域的採購韌性、證據生成、數位化護理整合和商業性夥伴關係，提出切實可行的策略和營運建議。

產業領導者應採取一系列切實可行的措施，以平衡臨床價值、營運韌性和商業性可行性。首先，應實現籌資策略多元化，減少對單一原料來源的依賴，同時認證替代供應商，以維持穩定的供應，並降低關稅造成的成本波動風險。其次，應優先建構兼顧產品系列和高利潤率特種產品的產品組合，這些特種產品需有臨床證據和真實世界數據支持，以證明其對患者的益處和經濟價值。

透過結合第二手資料、專家訪談和檢驗的嚴謹多方面調查方法，我們得出對經腸營養決策有用的實踐者層面的見解。

本調查方法結合了系統性的二手資料研究、有針對性的一手訪談以及嚴謹的檢驗，以確保研究結果的可靠性和對相關人員的相關性。二手資料包括同行評審的臨床文獻、監管指導文件、製造商技術文件和公共採購記錄。這些資訊來源揭示了產品選擇和市場趨勢背後的臨床和政策背景。一手訪談包括對臨床醫生、註冊營養師、醫院藥劑師、供應鏈經理和居家照護提供者進行結構化訪談，以了解他們的實踐模式、採購重點和營運挑戰。

對於經腸營養領域的相關人員，整合是將臨床特異性、供應彈性和以結果為導向的商業化聯繫起來的明確策略挑戰的結論。

總之，經腸營養系統正從商品化的供應模式轉向以結果主導的市場模式轉變，在這個市場中，配方特異性、供應鏈韌性和整合式服務交付決定著競爭優勢。相關人員必須平衡臨床需求與營運實際情況，透過投資實證實踐、實現供應鏈多元化以及採用能夠提高用藥依從性和改善真實世界臨床結果的數位化工具來實現這一目標。臨床團隊、採購、法規事務和銷售部門的領導者之間的跨職能協作對於實現這些轉變以及將獲得的洞見轉化為可執行的方案至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章經腸營養市場：依產品類型分類

  • 混合食物
  • 專用配方
    • 疾病特異性類型
      • 糖尿病
      • 對於肝臟
      • 呼吸系統
      • 腎
    • 富含纖維
    • 免疫調節
    • 含有益生菌
  • 標準配方
    • 模組化的
    • 寡聚物
    • 聚合物

第9章經腸營養市場：依形式分類

  • 液體
  • 粉末

第10章經腸營養市場：依給藥途徑分類

  • 口服營養
  • 腸內營養

第11章經腸營養市場：依分銷管道分類

  • 醫院藥房
  • 線上管道
  • 零售藥房

第12章經腸營養市場：依年齡層別分類

  • 成人版
  • 兒童

第13章經腸營養市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章經腸營養市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章經腸營養市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國經腸營養市場

第17章：中國經腸營養市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Danone SA
  • DSM Nutritional Products AG
  • Fresenius Kabi AG
  • Global Health Products, Inc.
  • Hormel Foods Corporation
  • Kate Farms Inc.
  • Mead Johnson & Company, LLC
  • Medtrition Inc.
  • Meiji Holdings Co., Ltd.
  • Nestle SA
  • Nutricia Advanced Medical Nutrition
  • Nutritional Medicinals, LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Perrigo Company plc
  • Real Food Blends LLC
  • Reckitt Benckiser Group PLC
  • Victus Inc.
Product Code: MRR-4348D129FAAF

The Enteral Nutrition Market was valued at USD 7.10 billion in 2025 and is projected to grow to USD 7.74 billion in 2026, with a CAGR of 10.17%, reaching USD 13.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.10 billion
Estimated Year [2026] USD 7.74 billion
Forecast Year [2032] USD 13.99 billion
CAGR (%) 10.17%

A strategic introduction explaining why enteral nutrition now demands integrated clinical, operational, and commercial strategies to drive better patient outcomes and system resilience

Enteral nutrition occupies a central role in acute and long-term clinical care, bridging the gap between medical necessity and patient-centered nutritional support. Clinicians and procurement leaders increasingly view enteral therapies not merely as consumables but as integral elements of care pathways where formulation choice, route of administration, and access models materially affect outcomes and healthcare resource utilization. As a result, informed decision-making demands an integrated view of clinical evidence, supply continuity, and commercial dynamics.

This executive summary sets the stage for a strategic assessment of the enteral nutrition environment by synthesizing drivers that influence product selection, adoption, and procurement. It also highlights the interplay between technological innovation, regulatory oversight, and evolving care settings such as in-hospital critical care, outpatient management, and home enteral nutrition. By situating clinical needs within operational realities, the introduction clarifies why stakeholders should prioritize resilience, patient-centered design, and evidence-based differentiation as core pillars of strategy going forward.

How clinical innovation, digital care models, and supply chain modernization are simultaneously reshaping product design, prescribing behavior, and distribution strategies in enteral nutrition

The enteral nutrition landscape is undergoing transformative shifts driven by clinical innovation, digital integration, and changing care settings. Formulation science has advanced beyond standard caloric replacement to include therapeutic modalities such as immune modulation, disease-specific nutrient blends, and microbiome-informed enrichment, prompting clinicians to refine prescribing practices based on individual patient phenotypes and comorbidities. Simultaneously, the proliferation of telehealth and remote patient monitoring enables more rigorous follow-up, adherence tracking, and timely product adjustments, which in turn influences product design and packaging requirements.

Operationally, increased pressure on hospital budgets and the continued expansion of home-based care have altered distribution priorities; payers and providers place higher value on demonstrable clinical outcomes and cost-of-care reductions than on unit price alone. This shift encourages manufacturers to pursue evidence-generation partnerships with health systems and to offer services that support training, patient education, and adherence. Moreover, supply chain modernization-through nearshoring, strategic inventory management, and digital traceability-has become a competitive differentiator as organizations seek to mitigate risk and ensure continuity of care.

Assessing the cumulative effects of 2025 tariff measures on raw material sourcing, supply chain resilience, and procurement strategies for enteral nutrition stakeholders

The introduction of tariffs affecting imported medical and nutritional inputs in 2025 has amplified attention on cost structures and supply chain exposure across the enteral nutrition value chain. Manufacturers that rely on imported raw materials, specialized ingredients, and finished-goods components have faced higher landed costs, prompting reassessment of sourcing strategies and, in some cases, incremental product reformulation to reduce tariff sensitivity. Procurement teams have responded by increasing scrutiny of total cost of ownership and by seeking contractual protections that allocate tariff risk more equitably along the supply chain.

Beyond direct cost implications, tariffs have accelerated conversations about local manufacturing capacity and strategic inventory positioning. For healthcare providers, the immediate consequence has been heightened emphasis on supplier diversification and contingency planning to avoid interruptions in clinically necessary supplies. For manufacturers, tariffs have created incentives to evaluate regional manufacturing hubs, qualify alternate suppliers, and invest in raw material substitution where clinically acceptable. In the medium term, these dynamics may also influence product labeling, packaging strategies, and the economics of value-added services tied to clinical outcomes and adherence.

A granular segmentation analysis explaining how product type, formulation, administration route, distribution channel, and age cohorts drive clinical choice and commercial prioritization

Segmentation analysis reveals differentiated opportunities and challenges across product types, forms, routes of administration, distribution channels, and age cohorts. In terms of product type, the market encompasses blenderized diets, specialized formulas, and standard formulas; within specialized formulas, further differentiation exists for disease-specific therapies, fiber-enriched compositions, immune-modulating products, and probiotic-supplemented blends, while disease-specific offerings can be tailored for diabetic, hepatic, pulmonary, and renal indications; standard formulas in turn can be modular, oligomeric, or polymeric. These distinctions matter because clinical prescribing behavior increasingly aligns with the specificity of the formulation and the evidence supporting targeted nutrient interventions.

Form factors such as liquid and powder influence logistics, storage, and patient adherence, with powders offering advantages in shelf life and shipping efficiency and liquids providing convenience for clinical settings. Route of administration splits between oral nutrition and tube feeding, each with unique clinical protocols, packaging needs, and caregiver education requirements. Distribution channels include hospital pharmacies, online channels, and retail pharmacies, and each channel requires tailored commercial and regulatory approaches to optimize availability and reimbursement. Age-based segmentation separates adult and pediatric cohorts, underscoring the need for age-appropriate nutrient profiles, dosing strategies, and packaging formats that support caregiver administration and regulatory compliance.

Regional competitive and regulatory contours across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine manufacturing priorities and market access approaches

Regional dynamics exhibit meaningful variation driven by healthcare infrastructure, reimbursement models, and manufacturing footprints across the Americas, Europe Middle East & Africa, and Asia-Pacific. The Americas typically feature consolidated hospital systems and a mature home care market where payer negotiations and value demonstration are pivotal to product uptake. In contrast, Europe Middle East & Africa presents a mosaic of regulatory environments and procurement approaches, where centralized tendering coexists with country-specific clinical guidelines and evolving reimbursement pathways. Asia-Pacific is characterized by heterogenous growth patterns, ranging from robust domestic manufacturing capacity in certain economies to rapidly expanding home nutrition services in urban centers.

These geographic differences influence strategic choices by manufacturers and distributors, including where to establish regional manufacturing or fill-and-finish operations, how to prioritize clinical evidence generation, and which distribution partnerships best enable market access. Furthermore, regulatory timelines and tariff regimes vary across these regions, affecting speed-to-market and the relative attractiveness of domestic versus export-oriented production strategies. Understanding these regional contours is therefore essential for aligning commercial investments with local payer expectations and clinical practice.

How top players differentiate through therapeutic specialization, supply chain strength, evidence partnerships, and integrated service offerings to secure clinical adoption

Leading organizations in the enteral nutrition space are differentiating through a combination of formulation innovation, clinical evidence generation, and supply chain investments. Some firms prioritize therapeutic specialization, developing disease-specific formulas supported by targeted clinical studies and real-world evidence collaborations with health systems. Others focus on operational excellence-optimizing manufacturing scale, investing in quality systems, and extending cold chain and packaging competencies to ensure product integrity. Strategic partnerships, contract manufacturing arrangements, and alliances with homecare providers and digital health platforms have emerged as effective ways to accelerate adoption and enhance service offerings.

Across the competitive landscape, successful players balance portfolio breadth with depth: they maintain standardized options for broad adoption while selectively investing in premium or specialty products that command differentiated clinical value. Additionally, companies that integrate educational services for clinicians and caregivers, leverage digital adherence tools, and demonstrate cost-of-care benefits in payer-facing materials tend to secure more favorable contracting outcomes. Finally, agility in regulatory compliance and the ability to respond to regional tariff or supply disruptions have become important determinants of sustained commercial performance.

Actionable strategic and operational recommendations to strengthen sourcing resilience, evidence generation, digital care integration, and commercial partnerships in enteral nutrition

Industry leaders should pursue a set of practical measures that align clinical value with operational resilience and commercial viability. First, diversify sourcing strategies to reduce exposure to single-origin raw materials and to mitigate tariff-driven cost volatility, while simultaneously qualifying alternate suppliers to maintain consistent supply. Second, prioritize formulation portfolios that balance broad-use standard formulas with higher-margin specialized products supported by clinical evidence and real-world data that demonstrate patient benefit and economic value.

Third, invest in digital tools and service models that improve adherence, support remote monitoring, and provide measurable outcomes data for payers and health systems. Fourth, strengthen partnerships with hospital pharmacies, homecare providers, and online distributors to create seamless patient journeys from prescription to home delivery. Fifth, evaluate regional manufacturing or fill-and-finish options where tariffs and logistics materially affect total landed cost, and ensure regulatory pathways are proactively managed. By taking these actions, leaders can reduce supply risk, increase clinical adoption, and position their offerings as integral components of value-based care initiatives.

A rigorous multi-method research approach combining secondary evidence, expert interviews, and triangulation to produce practitioner-relevant insights for enteral nutrition decisions

The research methodology combines systematic secondary research, targeted primary interviews, and rigorous triangulation to ensure the findings are robust and relevant to stakeholders. Secondary inputs include peer-reviewed clinical literature, regulatory guidance documents, manufacturer technical dossiers, and public procurement records; these sources frame the clinical and policy context that underpins product selection and market behavior. Primary research comprises structured interviews with clinicians, dietitians, hospital pharmacists, supply chain managers, and homecare providers to capture practice patterns, procurement priorities, and operational pain points.

Data were synthesized using triangulation methods to reconcile differences between published evidence and practitioner insights, and scenario analyses were employed to assess the operational implications of supply shocks, tariff shifts, and changes in care delivery models. Quality assurance protocols included cross-validation of key findings with subject-matter experts and a final editorial review to ensure clarity and applicability. Together, these methods produce a balanced, practitioner-focused evidence base suitable for informing procurement, clinical pathway design, and commercial strategy.

Concluding synthesis that ties clinical specificity, supply resilience, and outcome-focused commercialization into a clear strategic imperative for stakeholders in enteral nutrition

In conclusion, the enteral nutrition ecosystem is maturing from a commoditized supply model toward an outcome-driven market where formulation specificity, supply chain resilience, and integrated service offerings determine competitive advantage. Stakeholders must reconcile clinical imperatives with operational realities by investing in evidence generation, diversifying supply chains, and adopting digital tools that enhance adherence and real-world outcomes. These shifts require cross-functional collaboration among clinical teams, procurement, regulatory affairs, and commercial leaders to translate insights into actionable programs.

As organizations navigate tariff pressures, regional regulatory variation, and evolving care settings, the imperative is clear: align product development and commercial strategies with measurable clinical and economic value. Those who do will be better positioned to secure preferred contracting, support improved patient outcomes, and sustain growth in an increasingly complex and opportunity-rich environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteral Nutrition Market, by Product Type

  • 8.1. Blenderized Diet
  • 8.2. Specialized Formulas
    • 8.2.1. Disease Specific
      • 8.2.1.1. Diabetic
      • 8.2.1.2. Hepatic
      • 8.2.1.3. Pulmonary
      • 8.2.1.4. Renal
    • 8.2.2. Fiber Enriched
    • 8.2.3. Immune Modulating
    • 8.2.4. Probiotic Supplemented
  • 8.3. Standard Formulas
    • 8.3.1. Modular
    • 8.3.2. Oligomeric
    • 8.3.3. Polymeric

9. Enteral Nutrition Market, by Form

  • 9.1. Liquid
  • 9.2. Powder

10. Enteral Nutrition Market, by Route Of Administration

  • 10.1. Oral Nutrition
  • 10.2. Tube Feeding

11. Enteral Nutrition Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Channel
  • 11.3. Retail Pharmacies

12. Enteral Nutrition Market, by Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Enteral Nutrition Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Enteral Nutrition Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Enteral Nutrition Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Enteral Nutrition Market

17. China Enteral Nutrition Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. Danone S.A.
  • 18.9. DSM Nutritional Products AG
  • 18.10. Fresenius Kabi AG
  • 18.11. Global Health Products, Inc.
  • 18.12. Hormel Foods Corporation
  • 18.13. Kate Farms Inc.
  • 18.14. Mead Johnson & Company, LLC
  • 18.15. Medtrition Inc.
  • 18.16. Meiji Holdings Co., Ltd.
  • 18.17. Nestle S.A.
  • 18.18. Nutricia Advanced Medical Nutrition
  • 18.19. Nutritional Medicinals, LLC
  • 18.20. Otsuka Pharmaceutical Co., Ltd.
  • 18.21. Perrigo Company plc
  • 18.22. Real Food Blends LLC
  • 18.23. Reckitt Benckiser Group PLC
  • 18.24. Victus Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERAL NUTRITION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENTERAL NUTRITION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY BLENDERIZED DIET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY BLENDERIZED DIET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY BLENDERIZED DIET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DIABETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DIABETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DIABETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HEPATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HEPATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HEPATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FIBER ENRICHED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FIBER ENRICHED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FIBER ENRICHED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY IMMUNE MODULATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY IMMUNE MODULATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY IMMUNE MODULATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PROBIOTIC SUPPLEMENTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PROBIOTIC SUPPLEMENTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PROBIOTIC SUPPLEMENTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY MODULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY MODULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY MODULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY OLIGOMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY OLIGOMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY OLIGOMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POLYMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POLYMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POLYMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ORAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ORAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ORAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY TUBE FEEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY TUBE FEEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY TUBE FEEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ENTERAL NUTRITION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ENTERAL NUTRITION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ENTERAL NUTRITION MARKET SIZE, BY SPECIALIZED FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ENTERAL NUTRITION MARKET SIZE, BY DISEASE SPECIFIC, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ENTERAL NUTRITION MARKET SIZE, BY STANDARD FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ENTERAL NUTRITION MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ENTERAL NUTRITION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ENTERAL NUTRITION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ENTERAL NUTRITION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)